The inappropriate retention of neutrophils in the lung is a major driver of the excessive tissue 21 damage characteristic of respiratory inflammatory diseases including COPD, ARDS and cystic 22 42
fibrosis. The molecular programmes which orchestrate neutrophil recruitment to inflammatory 23 sites through chemotactic guidance have been well studied. However, how neutrophil 24 sensitivity to these cues is modulated during inflammation resolution is not understood. The 25 identification of neutrophil reverse migration as a mechanism of inflammation resolution and 26 the ability to modulate this therapeutically has identified a new target to treat inflammatory 27 disease. Here we investigate the role of the CXCL12/CXCR4 signalling axis in modulating 28 neutrophil retention at inflammatory sites. We used an in vivo tissue injury model to study 29 inflammation using transgenic zebrafish larvae. Expression of cxcl12a and cxcr4b during the 30 tissue damage response was assessed using in situ hybridisation and analysis of RNA 31 sequencing data. CRISPR/Cas9 was used to knockdown cxcl12a and cxcr4b in zebrafish 32 larvae. The CXCR4 antagonist AMD3100 was used to block the Cxcl12/Cxcr4 signalling axis 33 pharmacologically. We identified that cxcr4b and cxcl12a are expressed at the wound site in 34 zebrafish larvae during the inflammatory response. Following tail-fin transection, removal of 35 neutrophils from inflammatory sites is significantly increased in cxcr4b and cxcl12a CRISPR 36 knockdown larvae. Pharmacological inhibition of the Cxcl12/Cxcr4 signalling axis accelerates 37 inflammation resolution, an effect caused by an increase in neutrophil reverse migration. The 38 findings of this study suggest that CXCR4/CXCL12 signalling may play an important role in 39 neutrophil retention at inflammatory sites, identifying a potential new target for the therapeutic 40 removal of neutrophils from the lung in chronic inflammatory disease. 41
Introduction 45
The inappropriate retention of activated innate inflammatory cells at inflammatory sites is 46 major driver of chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis [1] . Neutrophils are the first cells recruited to the site of an inflammatory stimulus, 48
where they are potent anti-microbial effectors through the phagocytosis of foreign material, 49 generation of reactive oxygen species and the production of extracellular traps [2]- [4] . These 50 non-specific anti-microbial mechanisms promote a tissue microenvironment which is 51 unfavourable to pathogens, but at the expense of host tissue integrity [5] . Neutrophil removal 52 from inflammatory sites is therefore tightly regulated to minimise collateral tissue damage, 53 thereby preventing chronic inflammatory disease [6] . Despite the global burden of chronic 54 inflammatory diseases, there are currently no effective therapies to treat the neutrophilic 55 component of these conditions, highlighting a need to identify novel drug targets to promote 56 the successful resolution of inflammation. 57
It has been known for thirty years that neutrophils undergo apoptosis followed by efferocytosis 58 by macrophages, and this is the best characterised mechanism by which neutrophils are 59 removed from inflammatory sites [7], [8] . Although methods to both accelerate and delay 60 apoptosis have been identified [9]-[13], none of these are yet in clinical use for inflammatory 61 disease. More recently, reverse migration has been identified as a mechanism by which 62 neutrophils redistribute into the tissue or vasculature surrounding the inflammatory site, an 63 anti-inflammatory mechanism which is thought to disperse the inflammatory burden [12]- [15] . 64
The mechanisms governing this newer phenomenon are not fully understood, though it is clear 65 that the capacity of neutrophils to cause host tissue damage is increased when either 66 apoptosis or reverse migration are impaired, resulting in the inappropriate retention of 67 neutrophils at the inflammatory site [16] . Understanding neutrophil reverse migration 68 represents novel therapeutic avenues to treat neutrophil mediated chronic inflammation. 69
During inflammation, neutrophils respond to complex guidance cues provided in part by 70 chemokine gradients which promote the directed migration of neutrophils from the circulation 71 shown that this retention of neutrophils at inflammatory sites is both mechanistically important 80
[13], [16] , and can be manipulated therapeutically [10] , [12] , [18] , yet the molecular 81 mechanisms remain to be elucidated. 82 CXCR4 is a G protein coupled receptor expressed by many leukocytes, which exerts its 83 biological functions by signalling through its major ligand CXCL12 (formerly known as stromal 84 derived factor 1). CXCL12/CXCR4 signalling is a key retention signal for neutrophil release 85
into the blood circulation from hematopoietic tissues, the crucial role of which is highlighted in 86 patients with warts, hypogammaglobulinaemia, infection and myelokathesis (WHIM) 87 syndrome. Gain of function WHIM mutations result in increased CXCR4 signalling, the 88 consequence of which is severe neutropenia with increased neutrophil retention in the bone 89 marrow [20] . 90
There is growing evidence to support a role for CXCL12/CXCR4 in neutrophil retention in the 91 context of inflammatory disease. Tissue infiltrated neutrophils from patients with chronic 92 inflammatory lung diseases and rheumatoid arthritis have increased CXCR4 surface 93 expression [21] . Neutrophil surface expression of CXCR4 is increased after extravasation into 94 injured lungs in mice [22] and in human tissue samples, where pulmonary CXCL12 expression 95 increases during acute lung injury [23] . Additionally, the inhibition of CXCL12 using blocking 96 antibodies prevented the accumulation of neutrophils in the lung during the late stages of LPS 97 induced lung injury [22] . Based on this evidence we hypothesised that CXCL12/CXCR4 98 functions as a retention signal in the context of tissue damage, functioning to maintain active 99 neutrophils at the inflammatory site. 100
Here we present a new role for the CXCL12/CXCR4 signalling axis in the retention of 101 neutrophils at inflammatory sites and demonstrate a role for neutrophil retention signalling in 102 modulating inflammation resolution in zebrafish larvae. Using both pharmacological and 103 genetic approaches to manipulate the CXCL12/CXCR4 signalling axis, we demonstrate that 104 interruption of CXCR4 signalling accelerates inflammation resolution by increasing neutrophil 105 reverse migration. We have identified a druggable target which could be a therapeutic target 106 to remove inappropriately retained neutrophils from inflammatory sites during disease. 107
Results 109 cxcr4b and cxcl12a are expressed following tissue damage in zebrafish 110
Zebrafish have two paralogues for CXCR4 and CXCL12, following a genome duplication event 111
in teleost evolution. The expression of cxcr4a and cxcr4b is mutually exclusive in most cell 112 lineages, indicating roles in different tissues. [24] . To determine the gene expression of Cxcr4 113 and Cxcl12 during the cellular response to tissue damage in zebrafish larvae, we first 114 investigated neutrophil expression of cxcr4 and cxcl12. We studied published datasets 115 combining RNA sequencing of zebrafish larval neutrophils and single-cell RNA sequencing 116 data from adult zebrafish blood lineages [25], [26] . In adult zebrafish neutrophils, cxcr4b is 117 highly expressed by the neutrophil lineage whilst cxcr4a is undetectable ( Figure 1A Cxcl12a is expressed by a small population of adult zebrafish neutrophils, albeit far fewer than 119 cxcr4b, whilst cxcl12b is expressed by very few cells ( Figure 1C -D). We analysed larval stage 120 neutrophil RNA sequencing data [25] , and found that fragments per kilobase million (fpkm) 121 values for cxcr4b were over 100-fold higher than the fpkm values for cxcr4a ( Figure 1E ), 122
confirming that cxcr4b is the predominantly expressed isoform in larval zebrafish neutrophils. 123
Furthermore, we confirmed that expression of cxcl12a and cxcl12b was low in larval 124 neutrophils ( Figure 1F ). 125 and inflammation resolution occurs between 6-24hpi. Whole mount in situ hybridisation was 130 used to detect cxcl12a mRNA at the wound site in 3dpf larvae following tail fin transection. 131
Cxcl12a mRNA expression was detected in injured larvae as early as 6hpi during the 132 recruitment phase ( Figure 1G ). Interestingly, cxcl12a mRNA expression continued to increase 133 throughout the resolution phase up to 24hpi ( Figure 1G ) in keeping with other reports of cxcl12 134 expression following fin injury. These findings show the expression of cxcr4b by neutrophils 135 and cxcl12a at the tissue injury site during the inflammatory response in zebrafish. 136
Genetic manipulation of the CXCL12/CXCR4 signalling axis accelerates inflammation 137 resolution 138
After determining that cxcl12a was expressed at the wound site in injured larvae, we next 139 investigated neutrophil responses to tissue injury in the absence of the CXCL12/CXCR4 140 signalling axis. We hypothesised that if CXCL12/CXCR4 signalling was a neutrophil retention 141 signal, inhibition of this pathway would accelerate inflammation resolution. We used 142 CRISPR/Cas9 to study the role of Cxcl12a and Cxcr4b in neutrophilic inflammation resolution 143 using the TgBAC(mpx:GFP)i114 transgenic reporter line [28] . A crRNA targeting the pigment 144 gene tyrosinase (tyr) [29] was used for control injections and to allow for visual identification 145 of successful knockdown. Knockdown of tyr produces an albino phenotype in zebrafish larvae 146 (Supplemental Figure 1A -B) without affecting neutrophil development or the neutrophilic 147 inflammatory response (Supplemental Figure 1C -D). We generated cxcr4b or cxcl12a 148 'crispants' (newly generated "F0" CRISPR/Cas9-mediated mutants) and transected tail-fins at 149 2 dpf, counting neutrophils at the wound site at 4, 8 and 24 hpi (Figure 2A ). Neutrophil counts 150 in cxcr4b crispants were significantly increased at the wound site during the neutrophil 151 recruitment phase (4hpi), consistent with enhanced release of cxcr4b mutant neutrophils from 152 their site of production [30] ( Figure 2B ). Cxcl12a crispants showed no difference in neutrophil 153 recruitment ( Figure 2B ). No significant difference in neutrophil numbers at the wound site was 154 detected between groups at 8 and 24hpi ( Figure 2B ). To control for the increase in early 155 neutrophil recruitment measured in Cxcr4b crispants, we calculated percentage inflammation 156 resolution scores in individual larvae between 4 and 8 hpi. Both Cxcr4b and Cxcl12a crispants 157 had significantly higher percentage inflammation resolution compared to control larvae ( Figure  158 2C). Whole body neutrophil numbers were not affected in cxcr4b crispants, but were 159 significantly reduced in cxcl12a crispants ( Figure 2D ). These data demonstrate that loss of 160 Cxcl12/Cxcr4 signalling accelerates inflammation resolution in zebrafish larvae, suggesting 161 that the CXCL12/CXCR4 signalling axis is required for neutrophil retention at inflammatory 162 sites. 163
Pharmacological inhibition of CXCR4 accelerates inflammation resolution 164
Genetic knockdown of CXCR4 signalling causes neutrophil release from the caudal 165 haematopoietic tissue (CHT), enhancing neutrophil recruitment, confounding assessment of 166 inflammation resolution. To circumvent this, we used the CXCR4 antagonist AMD3100 to 167 block CXCR4 signalling in a time-sensitive fashion ( Figure 3A ). At 8hpi a significant decrease 168 in neutrophil counts at the wound site was detected in AMD3100 treated larvae ( Figure 3B ). 169
Percentage inflammation resolution was significantly higher in AMD3100 treated larvae 170 ( Figure 3C ), whilst whole body neutrophil counts were not affected by AMD3100 at 24 hours 171 post administration ( Figure 3D ). Together these data demonstrate that pharmacological 172 inhibition of CXCR4 in larvae which have mounted a normal response accelerates 173 inflammation resolution, further supporting a role for CXCL12/CXCR4 signalling in neutrophil 174 retention signalling at sites of tissue damage. 175
Inhibition of CXCL12/CXCR4 signalling increases neutrophil reverse migration 176
Two principal mechanisms of inflammation resolution have been described: neutrophil 177 apoptosis followed by efferocytosis by macrophages and reverse migration of neutrophils 178 away from inflammatory sites. We have previously proposed that neutrophil release from 179 inflammatory sites is best explained by the desensitisation of neutrophils to local chemokine 180 gradients [19] . This led us to the specific hypothesis that inhibition of CXCL12/CXCR4 181 signalling would accelerate reverse migration by accelerating neutrophil desensitisation to 182 CXCL12 gradients. To study neutrophil reverse migration, we used a well described 183 photoconversion approach to study the reverse migration of neutrophils from a wound site 184 [31] . AMD3100 was administered to TgBAC(mpx:GAL4-VP16); 185 Tg(UAS:Kaede)i222 (referred to as mpx:kaede) larvae at 5hpi and neutrophils at the wound 186 site were photoconverted and tracked during the resolution phase ( Figure 4A ). Neutrophil 187 migration away from the wound site was significantly higher in larvae treated with AMD3100 188 ( Figure 4B ), an effect which was not due to a difference in the number of photoconverted 189 neutrophils ( Figure 4C ). Together these data demonstrate that inhibition of CXCL12/CXCR4 190 signalling can increase inflammation resolution by accelerating neutrophil reverse migration, Computational modelling of reverse migration previously performed by our group 206 demonstrated that neutrophil reverse migration is best described as a process of stochastic 207 redistribution of neutrophils back into the tissue rather than their active migration away from 208 the wound site [19] . These data further support our suggestion that neutrophil reverse 209 migration is initiated following desensitisation to chemokine gradients at the wound site rather 
WHIM syndrome patients) prevents receptor internalisation and increases sensitivity to 243
Cxcl12a gradients, thus retaining them in the caudal hematopoietic tissue (CHT) 244
inappropriately [35] . Neutrophils in WHIM zebrafish larvae are unable to respond to wound-245 generated gradients effectively, hence neutrophil recruitment to inflammatory sites is reduced 246 in these larvae [35] . Conversely, in the Cxcr4b odysseus mutant where Cxcr4b signalling is 247 impaired, the number of neutrophils available to be recruited to tissue damage is increased 248
[30], thus our findings are in keeping with the F2 mutant phenotype [30] . Neutrophil recruitment 249 towards Cxcl12a was not increased in our experiments, although this could be attributed to 250
Cxcl12a larvae displaying significantly reduced whole body neutrophil counts. Inflammation 251 resolution was significantly increased in both Cxcr4b and Cxcl12a crispant larvae, suggesting 252 that genetic manipulation of both genes results in the same effect in terms of inflammation 253 resolution. 254
One of the advantages of using the zebrafish as a model to study inflammation is that chemical 255 compounds can be used to manipulate signalling pathways, where several compounds which 256 target neutrophils have been identified using this approach [9], [11], [12] . AMD3100 is a non-257 peptide bicyclam which is able to specifically antagonize the CXCR4 receptor at three main 258 interaction residues located around the main ligand binding pocket of CXCR4 in 259 transmembrane domains IV, VI and VII. Binding of AMD3100 competitively inhibits binding of 260 CXCL12 and prevents subsequent downstream signalling [44] . AMD3100 has been used to 261 inhibit the CXCL12/CXCR4 signalling axis in zebrafish larvae, where concentrations ranging 262 from 10-30µM have been administered to larvae through incubation in fish water for up to 24 263 hours [45], a concentration range which we remained within for our own experiments. Our 264 results from both genetic and pharmacological manipulation of Cxcr4b and Cxcl12a 265 demonstrate that inhibition of CXCL12/CXCR4 signalling accelerates inflammation resolution. 266
We propose that AMD3100 is able to accelerate inflammation and reverse migration by Reverse migration is impaired in Cxcr2 deficient zebrafish larvae where neutrophils are 279 inappropriately retained at the wound site [18] . It has been proposed that altered susceptibility 280 of neutrophils to gradients at the wound site in Cxcr2 deficient larvae drives their passive 281 migration away from the wound site. Our data are compatible with these findings, as the 282 CXCR4 and CXCR2 signalling axis is known to antagonistically regulate neutrophil retention 283 in other models [32] . It would be interesting to speculate that the combined outcome of 284 signalling through both CXCR4 and CXCR2 could modulate the reverse migration of 285 neutrophils during inflammation resolution. 286
Taken together our data demonstrate that inhibition of the CXCL12/CXCR4 signalling axis 287 drives the resolution of inflammation by increasing neutrophil reverse migration, and supports 288 the hypothesis that neutrophil desensitisation to gradients at the wound site results in their 289 reverse migration away from the wound site [18], [19] . These data add to the existing evidence 290 that neutrophil reverse migration can be targeted pharmacologically to drive the resolution of 291 inflammation. 292
Methods 293

Zebrafish husbandry and ethics 294
To study neutrophils during inflammation TgBAC(mpx:EGFP)i114 (known as mpx:GFP)[28] 295 zebrafish larvae were in-crossed. To study gene expression by whole mount in situ 296 hybridisation, wildtype pigment-less nacre[50] larvae were in-crossed. For reverse migration 297 assays, Tg(mpx:GAL4.vp16)sh267;Tg(UAS:Kaede)i222 (known as mpx:kaede) were in-298 crossed. All zebrafish were raised in the Bateson Centre at the University of Sheffield in UK 299
Home Office approved aquaria and maintained following standard protocols [51] . Tanks were 300 maintained at 28°C with a continuous re-circulating water supply and a daily light/dark cycle 301 of 14/10 hours. All procedures were performed on embryos less than 5.2 dpf which were 302 therefore outside of the Animals (Scientific Procedures) Act, to standards set by the UK Home 303
Office. 304
Neutrophil specific expression of zebrafish genes 305
Gene expression was assessed using an RNA sequencing database from FACS sorted GFP 306 positive cells from 5dpf zebrafish and FPKM values for genes of interest were extracted [25] 307 (data deposited on GEO under accession number GSE78954). For single cell analysis, gene 308 expression values were extracted from the BASiCz (Blood atlas of single cells in zebrafish) 309 cloud repository [26] . Cells of the neutrophil lineage were analysed for expression of cxcr4a, 310 cxcr4b, cxcl12a and cxcl12b. 311
WISH probe synthesis 312
The WISH antisense RNA probe for cxcl12a was synthesised from linearised plasmid DNA 313 obtained from a plasmid vector containing the zebrafish cxcl12a coding sequence. Following 314 transformation and DNA purification, the plasmid was linearised by restriction digest using 315 EcoR1 (New England Biolabs (NEB), Herts, UK). The RNA probe was transcribed from 316 linearised DNA using an SP6 RNA digoxigen labelling kit (Roche). 1μg of linearised DNA was 317 incubated in a final volume of 20μl containing transcription reagents and transcription reaction 318 was performed according to standard protocols (Roche). 319
Whole mount in situ hybridisation 320 Nacre larvae were anaesthetised in tricaine following tail fin transection at time points indicated 321 in the figure legends alongside uninjured, age-matched controls. No more than 20 larvae were 322 transferred to 1ml Eppendorf tubes and excess liquid was removed without damaging larvae. 323 1ml of paraformaldehyde (PFA) at 4°c was added to Eppendorf tubes for the fixation step, and 324 left overnight at 4°c. Larvae were washed and transferred into 100% methanol and stored at 325 -20°c for at least 24 hours prior to use. WISH was performed using standard protocols [52] 326 using an antisense DIG labelled probe for zebrafish cxcl12a. 327
CRISPR/Cas9 reagents 328
Synthetic SygRNA® consisting of crRNA and tracrRNA (Merck) in combination with cas9 329 nuclease protein (Merck) was used for gene editing. Transactivating RNAs (tracrRNA) and 330 gene specific CRISPR RNAs (crRNA) were resuspended to a concentration of 20µM in 331 nuclease free water containing 10mM Tris-hcl ph8. SygRNA® complexes were assembled on 332 ice immediately before injection using a 1:1:1 ratio of crRNA:tracrRNA:Cas9 protein. Gene-333 specific crRNAs to target cxcr4b and cxcl12a were designed using the online tool CHOPCHOP 334 (http://chopchop.cbu.uib.no/). We used the following crRNA sequences, where the PAM site 335 is indicated in brackets: cxcr4b: CAGCTCTGACTCCGGTTCTG(GGG) cxcl12a: 336 CTCTACCAGGCTGATGGGCT(TGG). 337
Microinjection of SygRNA® into embryos 338
A 1nl drop of SygRNA®:Cas9 protein complex was injected into mpx:GFP embryos at the one-339 cell stage. Embryos were collected at the one cell stage and injected using non-filament glass 340 capillary needles (Kwik-Fil TM Borosilicate Glass Capillaries, World Precision Instruments 341 (WPI), Herts, UK). RNA was prepared in sterile Eppendorf tubes. A graticule was used to 342 measure 0.5nl droplet sizes to allow for consistency of injections. Injections were performed 343 under a dissecting microscope attached to a microinjection rig (WPI) and a final volume of 1nl 344 was injected. 345
Genotyping of crispant larvae 346
To determine the efficiency of CRISPR/Cas9 to induce site-specific mutations in injected 347 larvae, we used restriction digest assays (Supplemental figure 2) . CRISPR guides were 348 designed to target sequences containing restriction digest sites, such that when indels were 349 introduced by DNA repair, the restriction site is disrupted. Genomic DNA was extracted from 350 individual larvae at 2dpf. Larvae were placed individually in 0.2ml PCR tubes in 90µl 50mM 351
NaOH and boiled at 95° for 20 minutes. 10µl Tris-HCL ph8 was added as a reaction buffer 352 and mixed thoroughly. RT-PCR using Firepol® (Solis BioDyne) was used to amplify a 235bp 353 region (for cxcr4b) and a 259bp region (for cxcl12a) around the PAM site. Gene specific 354 primers were designed using the Primer 3 web tool (http://primer3.ut.ee/). Primer sequences 355 were as follows:
TTCGAAAATTTGACCCAAAAGT. Restriction enzyme digests were then performed using bsII 358 at 55° for 2 hours (for cxcr4b) and bstXi (New England Biolabs) at 37° for 2 hours (for cxcl12a). 359
Products were run using gel electrophoresis on a 2% gel. 360
Inflammation assays in crispant larvae 361
To induce an inflammatory response, chorions of zebrafish larvae at 2dpf were removed using 362 sterile laboratory tweezers and larvae were anaesthetised in Tricaine (0.168 mg/ml; Sigma-363 Aldrich) in E3 media and visualised under a dissecting microscope. Tail-fins were transected 364 consistently using a scalpel blade (5mm depth, WPI) by slicing immediately posterior to the 365 circulatory loop, ensuring the circulatory loop remained intact as previously described [28] . 366
Larvae were maintained at 28°c in fresh E3 media in a 24 well plate. Neutrophils at the wound 367 site were counted at timepoints indicated in figure legends using a fluorescence stereo 368 microscope. 369
Compound treatment of larvae for inflammation resolution assays 370
To study the resolution of inflammation, neutrophils were counted at the wound site at intervals 371 during the resolution phase from 8-24 hours post injury in 2dpf mpx:GFP larvae, as indicated 372 in figure legends. Larvae were dechorionated and anaesthetised prior to injury by tail-fin 373 transection and left to recover at 28°c in fresh E3 media in petri dishes (60 larvae per plate). 374
Larvae were screened for good neutrophil recruitment (around 20 neutrophils at the wound 375 site) at 3.5hpi. AMD3100 (Sigma-aldrich) was administered to larvae at 4hpi through injection 376 into the duct of Cuvier at a final concentration of 20µM. AMD3100 was always tested alongside 377 the appropriate vehicle control. Neutrophils at the wound site were counted at 6hpi at the peak 378 of recruitment, and at 8hpi for inflammation resolution using a fluorescence stereo microscope 379 (Leica).
Percentage resolution calculations 381
To determine percentage resolution, experiments were performed with larvae maintained 382 separately in a 96 well plate to follow individual larvae over time. Percentage resolution was 383 calculated as ((Neutrophil counts at peak recruitment -neutrophil counts at 8hpi)/neutrophil 384 counts at peak recruitment)*100. 385
Whole body neutrophil counts 386
Whole body neutrophil counts were measured in mpx:GFP larvae at time points indicated in 387 figure legends. Larvae were mounted in 1% agarose with tricaine and a single slice image 388 was taken using a 4x NA objective lens on an Eclipse TE2000 U inverted compound 389 fluorescence microscope (Nikon UK Ltd., Kingston upon Thames, UK). A GFP-filter was used 390 at excitation of 488nm. Two images were taken per larvae, one of the head region and one of 391 the tail region. Neutrophils were counted manually from both images and combined to give a 392 whole body neutrophil count. 393
Reverse migration assay 394
Reverse migration assays were performed using larvae expressing the photoconvertible 395 protein kaede under the neutrophil specific mpx promoter: TgBAC(mpx:GAL4-VP16); 396 Tg(UAS:Kaede)i222. At 3dpf larvae were anaesthetised and injured by tail-fin transection and 397 left to recover at 28°c. Larvae were screened for good neutrophil recruitment at 4hpi. 
